SPRY
Ars Pharmaceuticals, Inc.
A maker of neffy, the first FDA-approved needle-free nasal spray for emergency treatment of severe allergic reactions (anaphylaxis), replacing the familiar auto-injector shot. Founded in 2015 by Richard Lowenthal, Dr. Sarina Tanimoto, and Dr. Robert Bell, the company's name is understood to reflect its focus on the allergic reaction system. neffy marked the first significant innovation in epinephrine delivery in over 35 years, offering a needle-free option for people who fear or avoid injectors.
CUSIP: 82835W108HealthcareUS1 holder
Total Value
$8.01M
Total Shares
1.00M
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
